title: Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.
abstract: There is currently intensive research on the design of novel human immunodeficiency virus type 1 (HIV-1) vaccine immunogens that can elicit potent neutralizing antibodies. A prerequisite for comparing and optimizing these strategies is the ability to precisely measure neutralizing antibody responses. To this end, we sought to develop an assay that directly quantifies single-round HIV-1 infection of peripheral blood mononuclear cells (PBMC). Initial experiments demonstrated that essentially all productively infected PBMC could be identified by flow cytometric detection of intracellular p24 antigen (p24-Ag). After infection of PBMC with HIV-1, p24(+) lymphocytes could be distinguished beginning 1 day postinfection, and the majority of CD8(-) T cells were p24-Ag positive by 3 to 4 days postinfection. To directly quantify first-round infection, we included a protease inhibitor in PBMC cultures. The resulting 2-day assay was highly sensitive and specific for the detection of HIV-1-infected PBMC. Serial dilutions of virus stocks demonstrated that the number of target cells infected was directly related to the amount of infectious virus input into the assay. In neutralization assays, the flow cytometric enumeration of first-round infection of PBMC provided quantitative data on the number of target cells infected and on the inactivation of infectious virus due to reaction with antibody. We also used this single-round assay to compare the percentage of cells expressing p24-Ag to the number of copies of HIV-1 gag per 100 PBMC. The precision and reproducibility of this assay will facilitate the measurement of HIV-1 neutralization, particularly incrementally improved neutralizing antibody responses generated by new candidate vaccines.
authors.affiliation: Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. jmascola@nih.gov
authors.forename: John R
authors.initials: JR
authors.lastname: Mascola
authors.forename: Mark K
authors.initials: MK
authors.lastname: Louder
authors.forename: Christine
authors.initials: C
authors.lastname: Winter
authors.forename: Ranjani
authors.initials: R
authors.lastname: Prabhakara
authors.forename: Stephen C
authors.initials: SC
authors.lastname: De Rosa
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Douek
authors.forename: Brenna J
authors.initials: BJ
authors.lastname: Hill
authors.forename: Dana
authors.initials: D
authors.lastname: Gabuzda
authors.forename: Mario
authors.initials: M
authors.lastname: Roederer
mesh_terms: D002478:Cells, Cultured; D005434:Flow Cytometry; D015483:HIV Antibodies / Q000276:immunology; D016655:HIV Core Protein p24 / Q000032:analysis; D015497:HIV-1 / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D009500:Neutralization Tests / Q000379:methods*; D011237:Predictive Value of Tests; D011480:Protease Inhibitors; D013601:T-Lymphocytes / Q000821:virology*
chemical_list: D015483:HIV Antibodies; D016655:HIV Core Protein p24; D011480:Protease Inhibitors